Education
About Us
Working with TipRanks
Follow Us
Zoetis (ZTS)
NYSE:ZTS
ZTS Stock Chart & Stats
$122.76
$1.04(0.64%)
At close: 4:00 PM EST
$122.76
$1.04(0.64%)
Day’s Range― - ―
52-Week Range$115.25 - $177.40
Previous CloseN/A
Volume625.10K
Average Volume (3M)5.58M
Market Cap
$53.87B
Enterprise Value$70.04B
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$7.27B
Price to Earnings (P/E)20.6
Beta0.55
Next Earnings
Feb 17, 2026EPS Estimate
1.4Next Dividend Ex-DateN/A
Dividend Yield1.69%
Share Statistics
EPS (TTM)1.70
Shares Outstanding440,693,200
10 Day Avg. Volume6,974,963
30 Day Avg. Volume5,584,665
Financial Highlights & Ratios
PEG Ratio3.88
Price to Book (P/B)15.51
Price to Sales (P/S)8.00
P/FCF Ratio32.20
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit10.55
Enterprise Value/Ebitda17.29
Forecast
1Y Price Target
$154.00Price Target Upside25.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)6.34
Revenue Forecast (FY)$9.44B
Bulls Say, Bears Say
Bulls Say
Market ExpansionZoetis noted the Animal Health market could double over the next decade, reaching $85-95B in sales by 2035.
New Product LaunchesZTS plans to roll out Lenivia, the first monoclonal antibody to alleviate OA pain in dogs for 3 months, providing convenience for pet owners and targeting new pet parents.
R&D And InnovationManagement outlined new developments across its R&D pipeline and announced 12 potential blockbusters in both established franchises and emerging areas.
Bears Say
Companion Animal SegmentThe big surprise was the slowdown in the company's US bread-and-butter companion animal health segment, which came in flat, as the company cited a step-up in competitive activity and a decline in vet clinic visits.
Market SentimentLingering concerns about competition have weighed on sentiment, compounded by Librela commercial hiccups.
Product TimelinesTimelines for therapeutics in areas such as oncology and cardiology have been extended, which may delay potential revenue streams.
Zoetis News
ZTS FAQ
What was Zoetis’s price range in the past 12 months?
Zoetis lowest stock price was $115.25 and its highest was $177.40 in the past 12 months.
What is Zoetis’s market cap?
Zoetis’s market cap is $53.87B.
When is Zoetis’s upcoming earnings report date?
Zoetis’s upcoming earnings report date is Feb 17, 2026 which is in 59 days.
How were Zoetis’s earnings last quarter?
Zoetis released its earnings results on Nov 04, 2025. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.621 by $0.079.
Is Zoetis overvalued?
According to Wall Street analysts Zoetis’s price is currently Undervalued.
Does Zoetis pay dividends?
Zoetis pays a Quarterly dividend of $0.5 which represents an annual dividend yield of 1.69%. See more information on Zoetis dividends here
What is Zoetis’s EPS estimate?
Zoetis’s EPS estimate is 1.4.
How many shares outstanding does Zoetis have?
Zoetis has 440,693,200 shares outstanding.
What happened to Zoetis’s price movement after its last earnings report?
Zoetis reported an EPS of $1.7 in its last earnings report, beating expectations of $1.621. Following the earnings report the stock price went down -13.779%.
Which hedge fund is a major shareholder of Zoetis?
Currently, no hedge funds are holding shares in ZTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zoetis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$154.00 (25.45% Upside)
$154.00 (25.45% Upside)
Blogger Sentiment
Bullish
ZTS Sentiment 94%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.51%
12-Months-Change
Fundamentals
Return on Equity
49.87%
Trailing 12-Months
Asset Growth
5.59%
Trailing 12-Months
Company Description
Zoetis
Zoetis Inc. is a leading global animal health company that discovers, develops, manufactures, and markets veterinary vaccines and medicines for livestock and companion animals. Established in 1952, Zoetis offers a wide range of products including anti-infectives, parasiticides, and medicines for pain management, as well as diagnostic products and genetic testing services. The company operates in two main segments: Livestock (which includes cattle, pigs, poultry, and aquaculture) and Companion Animals (which includes dogs and cats). Zoetis is committed to advancing animal health and improving food safety and security.
ZTS Company Deck
ZTS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Zoetis demonstrated strong performance in international markets and Livestock segment growth, with new product approvals enhancing future prospects. However, challenges in the OA pain franchise, U.S. market pressures, and competitive dynamics in dermatology posed significant headwinds.View all ZTS earnings summariesZTS Revenue Breakdown
19.74% Vaccines
23.26% Parasiticides
17.88% Dermatology
11.88% Anti-infectives
7.11% Other pharmaceuticals
3.17% Medicated feed additives
4.17% Animal health diagnostics
2.73% Other non-pharmaceuticals
0.86% Contract manufacturing & human health
9.19% Pain and sedation
ZTS Stock 12 Month Forecast
Average Price Target
$154.00
▲(25.45% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
19.00% Mutual Funds
26.47% Other Institutional Investors
29.78% Public Companies and Individual Investors